Shyndec subsidiary secures drug registration for anesthesia, antidote

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Sinopharm Industrial Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Salted Wu Yi Kui Ether Injection (1ml:1mg). This Type 4 chemical drug is intended for pre-anesthetic administration to inhibit glandular secretions and for emergency treatment of organophosphate poisoning.

The new approval is anticipated to enrich Shanghai Shyndec Pharmaceutical's product portfolio and enhance its market competitiveness, though it is not expected to significantly impact current operating performance. According to the Mi Nei website database, national sales of Salted Wu Yi Kui Ether Injection (1ml:1mg) in public medical institutions were CNY 51.763m, CNY 54.706m, and CNY 61.069m for 2022, 2023, and 2024 respectively.

Sinopharm Industrial's cumulative R&D investment for this project reached approximately CNY 3.6202m (unaudited). The company cautions that drug sales are subject to uncertainties from industry policies, tender procurement, and market conditions.